Neurocrine Biosciences stock (US64125C1099): Recent clinical trial advancements and market position

Neurocrine Biosciences advances its pipeline with new data on rare disease treatments, positioning the company as a key player in neurology for US investors amid ongoing FDA engagements.

Neurocrine Biosciences, a biopharmaceutical firm focused on neurological and endocrine disorders, recently shared updates on its clinical pipeline, including progress in treatments for congenital adrenal hyperplasia and tardive dyskinesia. These developments, highlighted in company communications, underscore the firm's commitment to addressing unmet medical needs. The stock has shown resilience in the biotech sector, trading on Nasdaq.

The stock traded at $142.50 USD on 05/13/2026 on Nasdaq, according to Yahoo Finance as of 05/13/2026. Investors are monitoring upcoming milestones such as potential regulatory submissions.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Neurocrine Biosciences, Inc.
• Sector/industry: Biotechnology / Neurology
• Headquarters/country: San Diego, USA
• Core markets: US, Europe
• Key revenue drivers: INGREZZA sales
• Home exchange/listing venue: Nasdaq (NBIX)
• Trading currency: USD

Neurocrine Biosciences: core business model

Neurocrine Biosciences develops therapies for complex neurological and endocrine conditions. Its lead product, INGREZZA (valbenazine), is approved for tardive dyskinesia and chorea associated with Huntington's disease. According to the company's 2025 annual report published 02/27/2026 on its IR site as of 02/27/2026, INGREZZA generated $2.3 billion in net product revenue for 2025, up 25% year-over-year.

The business model emphasizes rare disease focus with high barriers to entry, leveraging partnerships for commercialization. Neurocrine retains US rights for key assets while collaborating internationally, providing steady cash flow for R&D.

Main revenue and product drivers for Neurocrine Biosciences

INGREZZA remains the primary revenue driver, capturing over 90% of sales as per Q1 2026 results released 04/29/2026, with $572 million in quarterly revenue, according to company press release as of 04/29/2026. Expansion into new indications bolsters long-term growth.

Pipeline candidates like crinecerfont for congenital adrenal hyperplasia (CAH) showed promising Phase 3 data in late 2025, with NDA submission planned for H1 2026. This targets a US market of approximately 50,000 patients.

Industry trends and competitive position

The neurology biotech sector faces patent cliffs but benefits from rising demand for movement disorder therapies. Neurocrine holds a strong position with INGREZZA's first-to-market status, limited direct competition per EvaluatePharma as of 03/2026.

Why Neurocrine Biosciences matters for US investors

As a Nasdaq-listed biotech headquartered in San Diego, Neurocrine offers US investors exposure to innovative neurology treatments amid a $50 billion US neuro market. Its FDA-approved products ensure regulatory credibility relevant to domestic portfolios.

Conclusion

Neurocrine Biosciences continues to advance its neurology-focused pipeline with INGREZZA driving revenue growth and crinecerfont nearing approval. US investors track these developments closely given the company's Nasdaq listing and exposure to high-value rare disease markets. Market dynamics in biotech remain fluid with regulatory and clinical outcomes key to watch.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.